No profile data available.
Nymox Pharmaceutical Corporation (NYMXF) is a healthcare company in the urinary system treatment drugs industry, based in Nassau, Bahamas.
It reported revenue of $0 for fiscal year 2024, and net income of -$4.49 million. Its market capitalization was $3.36 million as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 8, 2026.
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of products for the aging population. Its lead drug candidate is Fexapotide Triflutate (NX-1207) for the treatment of benign prostatic hyperplasia and low-grade localized prostate cancer, as well as hepatocellular carcinoma.
Nymox Pharmaceutical reported $0 in revenue for fiscal year 2024.
$3.36 million as of October 8, 2026.
Listed companies of a similar size in the same industry (urinary system treatment drugs) include Unicycive Therapeutics, Inc. (UNCY), Cyclerion Therapeutics, Inc. (CYCN), Tvardi Therapeutics, Inc. (TVRD), ZyVersa Therapeutics, Inc. (ZVSA).